Media headlines about Corcept Therapeutics (NASDAQ:CORT) have trended somewhat positive on Thursday, according to Accern. The research firm ranks the sentiment of news coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Corcept Therapeutics earned a news impact score of 0.11 on Accern’s scale. Accern also gave media coverage about the biotechnology company an impact score of 46.3230124241748 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
Several brokerages have recently commented on CORT. BidaskClub downgraded Corcept Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday. Stifel Nicolaus assumed coverage on Corcept Therapeutics in a report on Thursday, August 31st. They set a “buy” rating and a $20.00 price objective on the stock. Piper Jaffray Companies set a $18.00 target price on shares of Corcept Therapeutics and gave the company a “buy” rating in a research report on Thursday, August 24th. Finally, Zacks Investment Research cut shares of Corcept Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, October 10th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and three have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average price target of $18.20.
Corcept Therapeutics (CORT) traded up $0.31 on Thursday, hitting $16.52. 1,434,160 shares of the company were exchanged, compared to its average volume of 1,111,681. The company has a market cap of $1,903.59, a PE ratio of 57.52 and a beta of 1.89. Corcept Therapeutics has a 1-year low of $6.70 and a 1-year high of $20.77.
Corcept Therapeutics (NASDAQ:CORT) last released its earnings results on Thursday, November 2nd. The biotechnology company reported $0.11 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.13 by ($0.02). The firm had revenue of $42.70 million for the quarter, compared to the consensus estimate of $41.64 million. Corcept Therapeutics had a return on equity of 58.17% and a net margin of 27.28%. Corcept Therapeutics’s revenue for the quarter was up 96.8% on a year-over-year basis. During the same quarter last year, the company posted $0.02 EPS. research analysts anticipate that Corcept Therapeutics will post 0.47 EPS for the current year.
In other news, Director G Leonard Baker, Jr. sold 30,000 shares of the stock in a transaction dated Monday, November 13th. The shares were sold at an average price of $17.59, for a total transaction of $527,700.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 19.20% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: This news story was originally reported by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are accessing this news story on another domain, it was stolen and republished in violation of US and international trademark & copyright law. The original version of this news story can be accessed at https://www.thelincolnianonline.com/2017/12/08/corcept-therapeutics-cort-getting-somewhat-favorable-press-coverage-accern-reports-updated-updated.html.
About Corcept Therapeutics
Corcept Therapeutics Incorporated is a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders. The Company is developing mifepristone, a compound that modulates the effects of cortisol by acting as a competitive antagonist at the glucocorticoid receptor (GR).
Receive News & Ratings for Corcept Therapeutics Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corcept Therapeutics Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.